CTOs on the Move

Spokane Inter Res Tech Ins

www.sirti.org

 
Spokane Inter Res Tech Ins is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sirti.org
  • 665 N Riverpoint Blvd
    Spokane, WA USA 99202
  • Phone: 509.358.2020

Executives

Name Title Contact Details

Similar Companies

Odan Laboratories

Odan Laboratories is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.

Pharmaceutical Buyers

Pharmaceutical Buyers is a Cedarhurst, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JHP Pharmaceutical

JHP Pharmaceutical is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.